Article Text

Download PDFPDF

AB0467 Efficacy and safety of assisted reproductive technologies (ART) in rheumatic patients: a multicenter study
  1. R Reggia1,
  2. H Sebbar1,
  3. L Andreoli1,
  4. A Hoxha2,
  5. M Larosa3,
  6. F Ceccarelli4,
  7. V Canti5,
  8. V Ramoni6,
  9. A Inversetti7,
  10. A Ruffatti2,
  11. A Doria3,
  12. F Conti4,
  13. G Valesini4,
  14. P Rovere Querini5,
  15. C Montecucco6,
  16. A Lojacono8,
  17. L Fallo8,
  18. A Tincani1
  1. 1Rheumatology and Clinical Immunology, ASST Spedali Civili di Brescia, BRESCIA
  2. 2Rheumatology Unit, Department of Medicine - DIMED
  3. 3Rheumatology Unit, Hospital and University of Padua, Padua
  4. 4Internal Medicine and Medical Specialties Department, Policlinico Umberto I, “La Sapienza” University of Rome, Rome
  5. 5Allergology and Clinical Immunology, U.O. Internal medicine, Ospedale San Raffaele, Milan
  6. 6Rheumatology Unit, IRCCS Policlinico San Matteo and University of Pavia, Pavia
  7. 7Department of Obstetrics and Gynaecology, Ospedale San Raffaele, Milan
  8. 8Maternal-Fetal Medicine, ASST Spedali Civili di Brescia, BRESCIA, Italy


Background Always more frequently rheumatic patients (pts) ask for Assisted Reproductive Technologies (ART) for infertility problems. The main concern is determined by the ovarian stimulation, associated with an increased risk of disease flare and thrombosis.

Objectives To describe a case series of ART cycles in pts affected by rheumatic diseases, analyzing pregnacy rate and outcome, fetal-maternal complications and disease flares.

Methods We included all the consecutive pts evaluated in the Pregnancy Clinic of 5 Italian Rheumatology Units after having performed ≥1 ART cycle from 1997 to 2016.

Results We included 60 pts: infertility was primary (no previous spontaneous conception) in 68% of cases, idiopathic in 76.5%, of male origin in 8.3%, of female origin in 15%, mixed in 0.2%. One hundred and eleven ART cycles were performed: 13IUI, 44FIVET (3eterologous), 53ICSI (14eterologous), 1embryodonation. Antiphospholipid antibodies were positive in 23 (38.3%) pts and in 45 (40.5%) cycles. Procedures were unstimulated in 14 (12.6%) stimulated in 97 (59.5%) cases: with GnRH-Antagonist in 26 (26.8%), GnRH-agonist in 60 (61.8%), gonadotropins only in 7 (7.3%) and with clomiphene in 4 (4.1%) cases. We registered 3 (3%) cases of Ovarian Hyperstimulation Syndrome, all after Agonist protocol. Overall we observed 46 pregnancies, with a pregnancy rate of 38.7% for omologous procedures and of 55.5% for eterologous. No miscarriages were reported. Pregnancies ended with 35 single and 5 twin birth, 6 are still ongoing: we recorded 4 (8.9%) perinatal deaths: 1 baby died at birth for multiple malformations and 3 died in the first days of life for extreme prematurity. One or more fetal complications were reported in 11 (27.5%) pregnancies: 3PROM, 3IUGR, 3oligohydramnios, 4fetal malformation (2 severe, 1multiple and fatal). The mean age of the women suffering from fetal complications was significantly lower (p:0.03). One or more maternal complications were reported in 13 (32.5%) pregnancies: 4gestational diabetis, 2thrombocytopenia, 2pre-eclampsia, 2placenta previa, 1hypothyroidism, 1gestational hypertension, 1cholestasis of pregnancy. Disease Flares were reported in 5 (12.5%) pregnancies: 4 articular (2 in RA patients, 2 in SLE patients), 1haematological (in SLE patient, after spontaneous therapy discontinuation). No cases of thrombosis were reported.During puerperium: 1 (2.5%) post-partum hemorrage (no LMWH ongoing), 1 articular flare (2.5%). Additional informations are available in Table 1.

Conclusions We didn't found any good reasons to discourage ART performance in rheumatic pts: the safety seems to be high and the complications rate is in line with that reported in general population. An adequate prophylaxis during stimulation, pregnancy and puerperium seems to provide a good protection from thrombotic complications.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.